Reported Sunday, Cue Biopharma's CUE-221 Shows 60% Complete Hives Resolution Twelve Weeks Off Treatment At 4 Mg/Kg In Phase 2 Chronic Spontaneous Urticaria Study Versus 24% For Omalizumab In Post Hoc Analysis
Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile
Clinically different efficacy profile observed relative to XOLAIR® (omalizumab) highlights potential for a fundamental mechanism-based biological difference
Login to comment